We use cookies to measure traffic and show relevant ads. By clicking Accept you agree to our use of analytics and advertising cookies.
FDA在DeLLphi-304研究后完全批准tarlatamab用于小细胞肺癌二线治疗。了解治疗突破和患者新选择。
